Literature DB >> 22535978

In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.

Edouard Bingen, Philippe Bidet, André Birgy, Elsa Sobral, Patricia Mariani, Robert Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22535978      PMCID： PMC3405603          DOI： 10.1128/JCM.00526-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  9 in total

1.  Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of extended-spectrum-Beta-lactamase-producing members of the enterobacteriaceae.

Authors:  Jennifer D Campbell; James S Lewis; M Leticia McElmeel; Letitia C Fulcher; James H Jorgensen
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

2.  Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae.

Authors:  Caroline Dallenne; Anaelle Da Costa; Dominique Decré; Christine Favier; Guillaume Arlet
Journal:  J Antimicrob Chemother       Date:  2010-01-12       Impact factor: 5.790

3.  Oral versus initial intravenous therapy for urinary tract infections in young febrile children.

Authors:  A Hoberman; E R Wald; R W Hickey; M Baskin; M Charron; M Majd; D H Kearney; E A Reynolds; J Ruley; J E Janosky
Journal:  Pediatrics       Date:  1999-07       Impact factor: 7.124

4.  Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children.

Authors:  Nathalie Bocquet; Aline Sergent Alaoui; Jean-Pierre Jais; Vincent Gajdos; Vincent Guigonis; Bernard Lacour; Gérard Chéron
Journal:  Pediatrics       Date:  2012-01-30       Impact factor: 7.124

Review 5.  Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin.

Authors:  D R Guay
Journal:  Pediatr Infect Dis J       Date:  2000-12       Impact factor: 2.129

6.  Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.

Authors:  G Manno; E Ugolotti; M L Belli; M L Fenu; L Romano; M Cruciani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-01-25       Impact factor: 3.267

7.  Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  B Balke; M Hogardt; S Schmoldt; L Hoy; H Weissbrodt; S Häussler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

Review 8.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 9.  Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide.

Authors:  L Drieux; F Brossier; W Sougakoff; V Jarlier
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067
  9 in total
  7 in total

1.  In vitro interaction between cefepime and amoxicillin-clavulanate against extended-spectrum β-lactamase-producing Escherichia coli.

Authors:  Edouard Bingen; Philippe Bidet; Camille D'humières; Elsa Sobral; Patricia Mariani-Kurkdjian; Robert Cohen
Journal:  Antimicrob Agents Chemother       Date:  2013-05       Impact factor: 5.191

2.  Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.

Authors:  B Rossi; J F Soubirou; F Chau; L Massias; S Dion; R Lepeule; B Fantin; A Lefort
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

3.  Characterization of extended-spectrum-beta-lactamase-producing Escherichia coli strains involved in maternal-fetal colonization: prevalence of E. coli ST131.

Authors:  André Birgy; Patricia Mariani-Kurkdjian; Philippe Bidet; Catherine Doit; Nathalie Genel; Céline Courroux; Guillaume Arlet; Edouard Bingen
Journal:  J Clin Microbiol       Date:  2013-03-20       Impact factor: 5.948

4.  Community-Onset Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Invasive Infections in Children in a University Hospital in France.

Authors:  Julie Toubiana; Sandra Timsit; Agnès Ferroni; Marie Grasseau; Xavier Nassif; Olivier Lortholary; Jean-Ralph Zahar; Martin Chalumeau
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

5.  Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.

Authors:  Fouad Madhi; Camille Jung; Sandra Timsit; Corinne Levy; Sandra Biscardi; Mathie Lorrot; Emmanuel Grimprel; Laure Hees; Irina Craiu; Aurelien Galerne; François Dubos; Emmanuel Cixous; Véronique Hentgen; Stéphane Béchet; Stéphane Bonacorsi; Robert Cohen
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

6.  Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam.

Authors:  Claire Amaris Hobson; Stéphane Bonacorsi; Didier Hocquet; André Baruchel; Mony Fahd; Thomas Storme; Raksamy Tang; Catherine Doit; Olivier Tenaillon; André Birgy
Journal:  Sci Rep       Date:  2020-01-17       Impact factor: 4.379

7.  Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study.

Authors:  Gabriel Lignieres; André Birgy; Camille Jung; Stéphane Bonacorsi; Corinne Levy; François Angoulvant; Emmanuel Grimprel; Marie Aliette Dommergues; Yves Gillet; Irina Craiu; Alexis Rybak; Loic De Pontual; François Dubos; Emmanuel Cixous; Vincent Gajdos; Didier Pinquier; Isabelle Andriantahina; Valérie Soussan-Banini; Emilie Georget; Elise Launay; Olivier Vignaud; Robert Cohen; Fouad Madhi
Journal:  PLoS One       Date:  2021-09-16       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.